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Available online 13 May 2016A62 year-oldmale patientwas admitted to thehospital due to anterior ST segment elevatedmyocardial infarction.
Thrombotic complication developed three times during the hospitalization after primary percutaneous coronary
intervention (PCI). Instent thrombus was identiﬁed despite the optimal medical therapy, new antiplatelet agents
and intravascular ultrasound guided PCI. Therefore, symptomswere controlledwithwarfarin+ clopidogrel treat-
ment. At the third month of warfarin + clopidogrel treatment, the patient was asymptomatic and no active elec-
trocardiographic changeswere observed. Stent thrombosis developing undernewantiplatelet agents constitutes a
great problem and there are no clear data for the solution.We described an interesting case in which we achieved
symptomatic control bywarfarin+clopidogrel in the stent thrombosis developing during the treatmentwith dual
antiplatelet therapy.
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an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Stent thrombosis
Warfarin
IVUSIntroduction
Current guidelines recommend timely applied primary percutane-
ous coronary intervention (PCI) for all patients with ST segment eleva-
tion myocardial infarction (STEMI).1 Despite the developments in
medical treatment and intervention methods, stent thrombosis (ST)
has still been a great challenge. There are limited data, in particular,
about what to do after ST developed under the treatment with new
antiplatelet agents.We have identiﬁed an interesting casewithout com-
plications underwarfarin+ clopidogrel treatment that did not have he-
reditary thrombophilia and had recurring thrombotic complications
despite the use of prasugrel, ticagrelor and intravascular ultrasound
(IVUS) guided PCI.
Case report
A 62 year old male patient without any additional risk factor except
hypertension was admitted to the hospital due to acute anterior ST seg-
ment elevatedmyocardial infarction (STEMI). In the coronary angiogra-
phy (CAG), LAD was found to be occluded in the proximal segment and
therewere no any signiﬁcant lesions in RCA and LCX. A 3.5 × 9mmbarert and it has not been published
part, before submission to the
rdiovascular Academy.
y. Production and hosting by Elsevmetal stent (BMS) was implanted to proximal LAD and a 3,5 × 28 mm
BMS was implanted to mid-region. Post-dilatation was applied to both
stents with 3,5 × 15 mm noncompliant balloon of Simpass (NCB) at
nominal pressure. 180mg ticagrelor, 300mg acetyl salicylate and intra-
venous abciximabwere administered during the procedure. The patient
was taken to post-MI follow-up and anginal complaints developed
again two days after PCI. In the patient's electrocardiography (ECG),
there were 2 mm ST segment elevation in the anterior leads, and CAG
was applied to the patient again. It has been found that proximal stent
was occluded with thrombosis. The lesion was reached with ﬂoppy
guidewire (FGW) and it was dilated with 4 × 18 mm NCB. Troﬁban
was started as intracoronary and systemic, ticagrelor discontinued
and 60 mg prasugrel was administered. After the patient was delivered
to the intense care unit in a stable condition, tiroﬁban infusion was
interrupted one day later. Because of chest pain and 1 mm ST segment
elevation in anterior leads, the patient was referred to CAG again one
day later. It was found that the proximal stent was occluded with
thrombus and the lesion was dilated with 4 × 18 mm NCB at 18 atm
pressure, following 1.5 × 15 mm balloon and 3.5 × 20 mm BMS at
nominal pressure was implanted. The examinations were sent in
terms of thrombosis tendency. No disease or condition leading to
thrombosiswas identiﬁed. IVUSwasplanned for thepatient. The expan-
sion of stent to lumen was evaluated with IVUS. It was observed that
proximal stent expanded insufﬁciently (Fig. 1). It was dilated again
with 4.5 × 15 mm NCB. It was checked with IVUS and seen that the
stent apposition was optimal. Due to presence of thrombus during the
IVUS (Fig. 2), thrombectomy was performed by thrombus aspiration
catheter. Intravenous tiroﬁban infusion was initiated and the patient
was referred to the intense care unit. However, angina and ECG changesier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. IVUS image demonstrated that proximal stent expanded insufﬁciently.
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of tiroﬁban. After readministration of intravenous tiroﬁban infusion
the patient's chest pain was regressed. ST was observed in LAD during
control CAG. Because of presence of TIMI 3 ﬂow, we decided to start
warfarin plus clopidogrel 75 mg daily and prasugrel was discontinued.
No angina developed and no ECG changes were found during the
monthly follow-up visits. We aimed the target INR value between
2.0 and 3.0 and the last two INR values of patients were 2.3 and 2.5.
The patient was discharged after three days without symptoms. At the
third month of the follow-up, the patient was asymptomatic, and
there were no changes in the ECG compared to the ECG examination
during discharge.Discussion
PCI in the treatment of acute coronary syndromes is the most sig-
niﬁcant and efﬁcient treatment option for morbidity and mortality.Fig. 2. IVUS image reveals optimal appositiona and thrombus formation (red arrow).However, ST is still a signiﬁcant problem in terms of mortality. We de-
scribed an interesting case having thrombotic complications three
times during the hospitalization that referred to the hospital due to an-
teriorMI. ST is a rare but usually catastrophic event that complicates the
stent implantation and it is associated with considerable mortality and
adverse outcomes due to abrupt vessel closure.2 It was deﬁned as the
occlusion originating in the peri-stent region or presence of a thrombus
originating in the peri-stent region in the presence of acute onset ische-
mic symptoms, or the presence of new ECG changes indicating acute is-
chemia or the presence of typical rise and fall in cardiac biomarkers.3 ST
etiology is multifactorial and it is associatedwith the procedural factors,
lesion and patient charecteristics.4 Although a signiﬁcant decrease was
reached in STwith the use of DES, ST has still been a signiﬁcantmortality
and morbidity problem. In our case, the stents implanted were BMS.
However, due to a large stent diameter, it may not be an appropriate
approach to associate ST to the stent type used.5
During the ﬁrst stent implantation, dual antiplatelet therapy with
ticagrelor was used, and the treatment was replaced with prasugrel
after stent thrombosis. However, ST developed again, considering that
hereditary thrombophilia was not found in our case. ST development
for 3 times makes the case quite complicated. It is known that IVUS
guided PCI decreases ST prominently. IVUS enables us to get informa-
tion about ST and to evaluate the stent underexpansion, arterial remod-
eling, neointimal structure and distribution.6 In our case, we applied
IVUS after second ST. After IVUS examination, we observed that the
proximal stent was underexpanded. Then, the stent diameter, which
was 3,5 mm, was dilated with 4,5 mm NCB. It was observed that the
stent expanded to the lumen completely. However, intraluminal throm-
buswas still found (Fig. 2). Thrombectomywas applied and TIMI III ﬂow
was provided. Upon the detection of intrastent thrombus in the control
angiography performed two days later, warfarin + clopidogrel treat-
ment was initiated as the maintenance therapy. No anginal complaint
occurred during this treatment, and no active ECG changes were ob-
served. After the discharge from hospital, it was seen that the symptom
and ECG did not change at 1st and 3rd months of follow-up.
The thrombotic process of patients continued although treatment
with IVUS guided PCI, glycoprotein 2b/3a antagonists and new anti-
platelet agents. No chest pain and active ECG change were observed
under warfarin + clopidogrel treatment. There has been no clear data
in the guides yet about the treatment method in case that ST develops
during treatment with new antiplatelet agents. As in our case, warfarin
usage may provide solution in such cases.
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